Investor Home

Corporate Profile

BeiGene is a commercial-stage biopharmaceutical company rooted in China that is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

We have three internally-developed late-stage clinical drug candidates:

  • Zanubrutinib (BGB-3111) — an investig...more >
Stock Quotemore >
BGNE (American Depositary Shares)

$162.30

 7.49 (4.41%)

04/25/18  10:10 a.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual Meeting - April 16, 2018
BEIJING, China and CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stag... Read More
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas - April 16, 2018
CAMBRIDGE, Mass. and BEIJING, China, April 16, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stag... Read More

Upcoming Events

20 Apr 2018
through
31 Oct 2018

E-mail Alerts

Sign up to receive e-mail alerts